Satavaptan Dose-Ranging Study in Normonatraemic Patients With Cirrhotic Ascites
Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine the optimal dose or range of doses of SR121463B for the
treatment of ascites when used concomitantly with a standard dose regimen of spironolactone
and furosemide.
The secondary objective is to determine the tolerability of different fixed doses of
SR121463B over a 14 day treatment period in cirrhotic ascites.